Peripheral T-cell Lymphoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin’s Lymphomas (NHL) that develops from mature T-cells. It originates from mature-stage white blood cells called T-cells and natural killer (NK) cells. A subtype of Non-Hodgkin’s Lymphoma (NHL) specifically affects T-cells and results when T-cells develop and grow abnormally. Patients with PTCL have a poor prognosis, with treatment characterized by multiple relapses and initial refractory disease. If stem cell transplantation is considered the next step in therapy, patients with relapsed disease are usually treated with combined chemotherapy (ICE) (ifosfamide, carboplatin, and etoposide). However, some regimens or transplants may not suit everyone due to their high toxicity levels. Single-agent treatments that are less toxic are also available and may induce long-term remission in such patients. Brentuximab vedotin (Adcetris), Belinostat (Beleodaq), pralatrexate (Folotyn), and romidepsin are examples of these treatments (Istodax). FDA has approved these drugs for patients who have relapsed or not responded to their first line of chemotherapy.

 

According to a literature survey, each year in the United States accounted for approximately 44% of the total incident cases with ~8,000. Among the EU5 countries, Germany had the highest incident population of PTCL, with 2,560 points.

 

The competitive landscape of Peripheral T-cell Lymphoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Peripheral T-cell Lymphoma across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Peripheral T-cell Lymphoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Peripheral T-cell Lymphoma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Belinostat          Spectrum Pharmaceuticals, Inc  Phase 2

2          Pralatrexate      Acrotech Biopharma LLC           Phase 1

3          HBI-8000          HUYABIO International, LLC.     Phase 2

4          AK104  Akeso Pharmaceuticals, Inc.      Phase 2

5          Pralatrexate      Mundipharma K.K.        Phase 2

6          KW-0761          Kyowa Kirin, Inc.           Phase 2

7          Chidamide        Chipscreen Biosciences, Ltd.     Phase 1

8          SHC014748M   Nanjing Sanhome Pharmaceutical, Co., Ltd.            Phase 2

9          Duvelisib           SecuraBio         Phase 2

10        GB226  Genor Biopharma Co., Ltd.        Phase 2

Continued